3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
104
Fallopian Tube Neoplasms
47
Carcinoma, Ovarian Epithelial
27
Neoplasms
12
Breast Neoplasms
7
Neoplasm Metastasis
5
Recurrence
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Peritoneal Neoplasms
3
Ovarian Cancer Recurrent
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Multiple Myeloma
2
Lung Neoplasms
2
Disease Progression
2
Colorectal Neoplasms
2
Breast Neoplasms, Male
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sezary Syndrome
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Interventions
Paclitaxel
2
Nivolumab
2
Gemcitabine
2
Bevacizumab
2
rucaparib
1
pembrolizumab
1
liposomal doxorubicin
1
dostarlimab
1
Taxes
1
Sunitinib
1
Ipilimumab
1
Immunoglobulin G
1
Doxorubicin
1
Docetaxel
1
Disulfides
1
Celecoxib
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
liposomal doxorubicin
×
Gynecologic
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled